This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health-Care Reformer: Under the Radar

BOSTON ( TheStreet) -- TheStreet's stock model upgraded MedQuist (MEDQ) to "hold" on Tuesday after the medical-transcription company posted a fourth-quarter profit.

MedQuist is larger than rival Transcend Services (TRCR), which is rated "buy," though the entrance of larger competitors is a concern. Wal-Mart (WMT - Get Report) began a digitization partnership with eClinicalWorks and Dell (DELL) last year.

Still, MedQuist and Transcend are worth consideration.

MedQuist swung to a fourth-quarter profit of $5.9 million, or 16 cents a share, from a loss of $60 million, or $1.61, a year earlier. The company's operating margin widened from 6.8% to 15%. Its balance sheet contains $25 million of cash, equating to an ample quick ratio of 1.3, and no debt. Still, cash fell 37% from a year earlier. Return on equity, a measure of profitability, climbed to 20%.

MedQuist sells voice-recognition software, translating physicians' words into electronic documents, which are then edited and formatted in its proprietary platform. This process improves workflow productivity by an estimated 50%. MedQuist's suite of products reduces the need for hospitals' technical staff, which raises objections from professionals with self-preservation instincts.

President Barack Obama allocated $20 billion of stimulus money to medical-record digitization, hoping to transform all paper to code by 2014. Companies like Cerner (CERN - Get Report) capitalized on the stimulus. MedQuist offers the next logical step in the process of overhaul. The company's net cash position, proven platform and growing customer base make it an attractive investment. Philips Electronics was once a majority shareholder, but divested its 70% stake in 2007.

India- and Maryland-based CBay Systems acquired the majority ownership from Philips, but MedQuist continues to operate as a publicly traded entity. Between the two companies, there is a customer base of more than 1,700 hospitals. CBay's other subsidiary, Mirrus Systems, provides medical billing and receivables management. In a country where health care costs are exorbitant, these three firms, which offer tangible savings, are poised to grow.

During the past three years, MedQuist has boosted profit 50% annually, on average. Its stock, however, has fallen 4.4%, on average, over the same period. The poor performance has deterred investors from bidding up the shares. MedQuist stock sells for a price-to-book ratio of 2.9, a price-to-sales ratio of 1.1 and a price-to-cash-flow ratio of 7.4, reflecting 45%, 79% and 76% discounts to industry averages. The stock has jumped 23% this year.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DELL $0.00 0.00%
CERN $55.73 0.02%
WMT $66.89 -0.45%
AAPL $93.00 -0.66%
FB $118.13 0.06%


Chart of I:DJI
DOW 17,692.42 +41.16 0.23%
S&P 500 2,054.58 +3.46 0.17%
NASDAQ 4,733.4520 +7.8130 0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs